Impact of Statin Use on Recurrence or Survival After Surgical Curative Resection of Non-Small Cell Lung Cancer. (16th May 2018)

• Record Type: Journal Article
• Authors: Oh, Tak Kyu; Kim, Kwhanmien; Jheon, Sanghoon; Lee, Jaebong; Do, Sang-Hwan; Hwang, Jung-Won; Kim, Hyo Jin; Song, In-Ae
• Is Part Of: Cancer control. Volume 25:Number 1(2018)
• Publication Date: 2018-05-16
• Subjects: cancer risk -- cancer survival -- lung cancer -- metastasis -- NSCLC; Cancer -- Prevention -- Periodicals; Cancer -- Diagnosis -- Periodicals; Cancer -- Treatment -- Periodicals; Cancer -- Palliative treatment -- Periodicals; Cancer -- Prevention; Medical Oncology; Neoplasms -- prevention & control; Neoplasms -- therapy; Electronic journals; Periodicals; Periodicals; 616.994005
• DOI: 10.1177/1073274818778000
• Languages: English
• ISSNs: 1073-2748

Abstract

Statins are known for their anticancer effects, and many studies have shown the effectiveness of statins for cancer prevention and improvement of cancer-related long-term oncologic outcome. However, their effectiveness on recurrence or survival of non-small cell lung cancer (NSCLC) after curative resection remains unknown. This was a retrospective cohort study that assessed the medical records of patients who were diagnosed with NSCLC and treated with curative resection at a tertiary care hospital between August 2003 and July 2012. The primary outcome was the comparison of postoperative overall survival (OS) and recurrence-free survival (RFS) between the statin group of patients, who were administered statins at least 1 month before the surgery and continued it after the surgery, and the nonstatin group of patients, who were not administered statins. Propensity score (PS) matching was used to balance the 2 groups, and the analysis was performed using a Cox proportional hazards model. In total, 994 patients with NSCLC were included in the final analysis: 135 patients in the statin group and 859 patients in the nonstatin group. After PS matching, there was no significant difference in postoperative recurrence ( P = .862) or death ( P = .074) between the statin group and the nonstatin group. Similarly, there was no significant difference in postoperative RFS ( P = .862) and OS ( P = .072) between the 2 groups after PS matching. This study demonstrated that statin administration had no significant association with recurrence or survival after NSCLC treatment.